MiMedx Group Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名48/404位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价12.20。中期看,股价处于平稳状态。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
MiMedx Group Inc评分
相关信息
行业排名
48 / 404
全市场排名
133 / 4563
所属行业
生物技术与医疗研究
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
5
位分析师
买入
评级
12.200
目标均价
+82.63%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
MiMedx Group Inc亮点
亮点风险
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
公司代码MDXG
公司MiMedx Group Inc
CEOCapper (Joseph H)
网址https://mimedx.com/
常见问题
MiMedx Group Inc(MDXG)的当前股价是多少?
MiMedx Group Inc(MDXG)的当前股价是 6.900。
MiMedx Group Inc的股票代码是什么?
MiMedx Group Inc的股票代码是MDXG。
MiMedx Group Inc股票的52周最高点是多少?
MiMedx Group Inc股票的52周最高点是9.710。
MiMedx Group Inc股票的52周最低点是多少?
MiMedx Group Inc股票的52周最低点是5.790。
MiMedx Group Inc的市值是多少?
MiMedx Group Inc的市值是1.02B。
MiMedx Group Inc的净利润是多少?
MiMedx Group Inc的净利润为42.42M。
现在MiMedx Group Inc(MDXG)的股票是买入、持有还是卖出?
根据分析师评级,MiMedx Group Inc(MDXG)的总体评级为买入,目标价格为12.200。